CO4940427A1 - Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina - Google Patents

Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina

Info

Publication number
CO4940427A1
CO4940427A1 CO98014184A CO98014184A CO4940427A1 CO 4940427 A1 CO4940427 A1 CO 4940427A1 CO 98014184 A CO98014184 A CO 98014184A CO 98014184 A CO98014184 A CO 98014184A CO 4940427 A1 CO4940427 A1 CO 4940427A1
Authority
CO
Colombia
Prior art keywords
composition
prostaglandine
increasing
present
agent
Prior art date
Application number
CO98014184A
Other languages
English (en)
Inventor
Kenneth Warren Reed
Yen Shau-Fong
Mary Sou
Flinn Peacock Regina
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO4940427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO4940427A1 publication Critical patent/CO4940427A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se relaciona con una composición lacual comprende: a) un agente activo de prostaglandina que se selecciona a partir del grupo que consiste en prostaglandinas, metabolitos de las mismas, derivados de las mismas, sales de las mismas y mezclas de las mismas; b) un conservador oftálmico; c) un agente de ajuste de tonicidad no iónico, en donde este agente de tonicidad no iónico está presente en una concentración suficiente para: i) ajustar la tonicidad de la composición, y ii) incrementar la efectividad del conservador; y d) un vehículo oftalmológicamente aceptable.
CO98014184A 1997-03-17 1998-03-13 Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina CO4940427A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
CO4940427A1 true CO4940427A1 (es) 2000-07-24

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98014184A CO4940427A1 (es) 1997-03-17 1998-03-13 Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina

Country Status (33)

Country Link
EP (1) EP0969846B2 (es)
JP (2) JP4920124B2 (es)
KR (1) KR100555818B1 (es)
CN (1) CN1236775C (es)
AR (2) AR002194A1 (es)
AT (1) ATE257385T1 (es)
AU (1) AU738781B2 (es)
BR (2) BR9808016A (es)
CA (1) CA2280089C (es)
CL (1) CL2009001870A1 (es)
CO (1) CO4940427A1 (es)
CY (1) CY2526B1 (es)
CZ (1) CZ299833B6 (es)
DE (1) DE69820997T3 (es)
DK (1) DK0969846T4 (es)
EE (1) EE04091B1 (es)
ES (1) ES2214706T5 (es)
HK (1) HK1026841A1 (es)
HU (1) HU228896B1 (es)
ID (1) ID22389A (es)
IL (1) IL131041A0 (es)
MY (1) MY122237A (es)
NO (1) NO327713B1 (es)
NZ (1) NZ337322A (es)
PE (1) PE61899A1 (es)
PL (1) PL197509B1 (es)
PT (1) PT969846E (es)
RU (1) RU2197970C2 (es)
SI (1) SI0969846T2 (es)
TW (1) TW527187B (es)
UA (1) UA63938C2 (es)
WO (1) WO1998041208A1 (es)
ZA (1) ZA982188B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
JP4000505B2 (ja) * 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
CA2422031C (en) * 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
AU2002218527A1 (en) * 2000-12-05 2002-06-18 Sankyo Company Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
US20070208068A1 (en) * 2004-03-18 2007-09-06 R-Tech Ueno, Ltd. & Astellas Pharma Inc. Aqueous Composition Comprising Thiazole Derivative
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
US8030349B2 (en) * 2005-08-02 2011-10-04 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable medicament
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US20090062381A1 (en) * 2006-03-13 2009-03-05 Ryu Hirata Aqueous composition
BRPI0709549A2 (pt) * 2006-03-17 2011-07-19 Johnson & Johnson Vision Care métodos para estabilizar composições instáveis oxidativamente
RU2465898C2 (ru) * 2006-10-31 2012-11-10 Алькон Рисерч, Лтд. Модуляторы связывания pai-1 для лечения глазных болезней
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
CA2702082A1 (en) * 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
DE202009019116U1 (de) * 2008-03-17 2016-08-01 Alcon Research, Ltd. Wässrige pharmazeutische Zusammensetzungen, die Borat-Polyol-Komplexe enthalten
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
CN108969482A (zh) 2011-12-07 2018-12-11 阿勒根公司 用盐敏性乳液体系对人泪液膜进行有效脂质递送
NZ732058A (en) 2014-11-25 2023-06-30 Allergan Inc Stabilized omega-3 ophthalmic compositions
CN113164043A (zh) * 2018-09-21 2021-07-23 奥夫博医疗创新有限公司 用于青光眼的组合物和方法
CN117050817A (zh) 2019-04-12 2023-11-14 埃科莱布美国股份有限公司 抗微生物多用途清洁剂及其制备和使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
CN1236775C (zh) 2006-01-18
JP2001515502A (ja) 2001-09-18
NO327713B1 (no) 2009-09-14
EE9900410A (et) 2000-04-17
SI0969846T1 (en) 2004-06-30
AU7035398A (en) 1998-10-12
DE69820997T3 (de) 2011-10-06
AU738781B2 (en) 2001-09-27
BRPI9816218B1 (pt) 2016-04-12
PL197509B1 (pl) 2008-04-30
DE69820997D1 (de) 2004-02-12
IL131041A0 (en) 2001-01-28
PT969846E (pt) 2004-05-31
BR9808016A (pt) 2000-03-08
NZ337322A (en) 2001-05-25
PL335168A1 (en) 2000-04-10
CA2280089A1 (en) 1998-09-24
KR20000076330A (ko) 2000-12-26
SI0969846T2 (sl) 2010-12-31
EP0969846B1 (en) 2004-01-07
HU228896B1 (en) 2013-06-28
HK1026841A1 (en) 2000-12-29
PE61899A1 (es) 1999-06-30
EE04091B1 (et) 2003-08-15
KR100555818B1 (ko) 2006-03-03
UA63938C2 (uk) 2004-02-16
CA2280089C (en) 2009-03-03
JP4920124B2 (ja) 2012-04-18
CY2526B1 (en) 2006-02-08
DK0969846T4 (da) 2010-12-20
CL2009001870A1 (es) 2010-01-22
ID22389A (id) 1999-10-07
ATE257385T1 (de) 2004-01-15
ES2214706T3 (es) 2004-09-16
MY122237A (en) 2006-04-29
AR002194A1 (es) 1998-01-07
TW527187B (en) 2003-04-11
DK0969846T3 (da) 2004-04-13
WO1998041208A1 (en) 1998-09-24
ES2214706T5 (es) 2011-02-02
HUP0002194A3 (en) 2012-08-28
RU2197970C2 (ru) 2003-02-10
DE69820997T2 (de) 2004-12-09
NO994481L (no) 1999-09-16
EP0969846B2 (en) 2010-08-25
JP2010043110A (ja) 2010-02-25
CZ325799A3 (cs) 2000-01-12
EP0969846A1 (en) 2000-01-12
NO994481D0 (no) 1999-09-16
AR011192A1 (es) 2000-08-02
ZA982188B (en) 1998-09-17
HUP0002194A2 (hu) 2000-12-28
CZ299833B6 (cs) 2008-12-10
CN1249687A (zh) 2000-04-05

Similar Documents

Publication Publication Date Title
CO4940427A1 (es) Metodo para incrementar la eficiencia del conservador en una composicion de prostaglandina
PT1187601E (pt) Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
RU2291860C3 (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
RU99121641A (ru) Композиции и способы, предназначенные для снижения глазной гипертензии
AR039434A1 (es) Composiciones y metodo para controlar el mal olor que comprenden agentes de control de olor y microcapsulas que contienen un material activo
CO4750715A1 (es) Metodos para la limpieza e higiene de productos agricolas, composiciones y articulos de comercio
AR019147A1 (es) Una formulacion de jarabe que contiene antihistaminico
CO5050388A1 (es) Formulaciones de bromo oxidantes, estables, metodos de fabricacion de las mismas y metodos de uso para el control del microensuciamiento
ES2162614T1 (es) Composiciones formadoras de pelicula que comprenden almidones modificados e iota-carragaenina y metodo para producir capsulas blandas usando las mismas.
ES2178263T3 (es) Composiciones oftarmologicas que contienen un glicosido cationico y unagente terapeutico anionico.
ES542041A0 (es) Procedimiento para la obtencion de una composicion detergente a base de un tenso activo no ionico eficaz a baja temperatura.
AR021949A1 (es) UNA COMPOSICIONES ToPICA ,SU USO, Y, UN MÉTODO COSMÉTICO QUE LA UTILIZA.
ES2184836T3 (es) Composiciones que contienen derivados de azol para aplicacion topica en la piel.
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
KR890006241A (ko) 설사약
ES2183148T3 (es) Composiciones oftalmicas que contienen un inhibidor de anhidrasa carbonica y de la goma de xantano.
ES2195393T3 (es) Diesteres lipofilos de agentes quelantes.
BR9908217A (pt) Composição desodorante, e, processo para inibição de odor corporal
ATE295165T1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
PT86050A (fr) Procede de regeneration du tournesol par embryogenese
JPS53144520A (en) Stabilization of unsaturated tert-amines or their quaternary ammonium salts
KR970010742A (ko) 프로스타글란딘 유도체
ATE270869T1 (de) ZUSAMMENSETZUNG MIT KONTINUIERLICHER WÄSSERIGER PHASE, DIE L-2-OXOTHIAZOLIDIN- 4-CARBONSÄURE ENTHÄLTß.
NO986041L (no) FremgangsmÕte ved behandling av plantesykdom
GB1472084A (en) Composition and method for sterilizing contact lenses